Developing a tumor-specific vaccine for pancreatic cancer in the future
Karen Geboes, MD, PhD, UZ Gent – University Hospital Ghent, Ghent, Belgium, emphasizes the need for higher cure rates in patients with resectable pancreatic cancers. Standard treatment includes surgery followed by chemotherapy with FOLFIRINOX. Future research aims to conduct a global study, which will investigate the administration of a tumor-specific vaccine in the adjuvant setting. This interview took place at the 39th Annual Meeting SITC 2024 at Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
